With a market cap of $18 billion, Indiana-based Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company specializing in musculoskeletal healthcare. Founded in 1927, it focuses on the design and manufacture of orthopedic products for bones, joints, and supporting tissues.
The company is slated to announce its fiscal Q1 2026 results before the market opens on Monday, May 4. Ahead of the event, analysts expect Zimmer Biomet to report an adjusted EPS of $1.86, up 2.8% from $1.81 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in each of the past four quarterly reports, which is admirable.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts predict the medical device maker to report adjusted EPS of $8.39, a 2.3% rise from $8.20 in fiscal 2025. Looking forward, adjusted EPS is projected to improve 6.3% year over year to $8.92 in fiscal 2027.
www.barchart.comShares of Zimmer Biomet have declined 10.1% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 25.1% increase and the Health Care Select Sector SPDR Fund's (XLV) 7.6% rise over the same period.
www.barchart.comOn Feb. 23, Zimmer Biomet announced that its Board of Directors had approved a quarterly cash dividend for the first quarter of 2026, reinforcing its commitment to returning capital to shareholders. The company will distribute a dividend of $0.24 per share, payable on or around April 30, 2026.
Analysts' consensus rating on ZBH stock is skeptical, with an overall "Hold" rating. Among 27 analysts covering the stock, six recommend a "Strong Buy,” one has a "Moderate Buy" rating, 17 give a "Hold" rating, and three have a "Strong Sell.” The average analyst price target for Zimmer Biomet is $102.14, indicating a potential upside of 9.8% from the current levels.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
S&P Futures Waver With All Eyes on Key U.S. Inflation Data, U.S.-Iran Talks Awaited Up 24% in 2026 and Yielding 3.1%, How Should You Play SHEL Stock Amid an Iran Ceasefire? As Amazon Takes on Chipmakers, Should You Buy AMZN Stock Here? Down More Than 30% from All-Time Highs, Should You Buy the Tesla Stock Dip?